According to China Pharma, omeprazole is widely utilized to treat gastroesophageal reflux disease, and is highly effective in other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison syndrome. Zhilin Li, president and CEO of China Pharma, said: "We are very pleased that the SFDA has approved China Pharma's production of omeprazole sodium injections. While most oral omeprazole preparations are enteric-coated due to the rapid degradation of the drug in the acidic conditions of the stomach; our injection product is formulated in freeze-dried powder, as a result, it enters the blood circulation faster and works efficiently toward absorption and avoiding degradation. "We believe that this approval provides us with an exciting opportunity to extend our product portfolio, and we expect it to create value for our patients and shareholders over time." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon For full details for CPHI click here.
![]()
Email Print Archives Feedback Email Article Link
Close X
Related News [CPHI]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|